Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas

NCT00937495 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00937495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00937495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
June 30, 2011
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult soft tissue sarcoma, stage iii adult soft tissue sarcoma, stage iv adult soft tissue sarcoma